Lacutoclax
Phase 2
Lacutoclax is one of 17 therapeutic programs targeting Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
17 competitors in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
#DrugCompanyPhaseTrials
1Jaypirca
Eli LillyApproved
Zydelig
GileadApproved
Rituxan
RochePhase 3
Venclexta
AbbViePhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Nemtabrutinib
Merck & Co.Phase 3
Gazyva
RochePhase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lacutoclax. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]